Scientific Sessions 2024  /  GLP-1RAs and Beyond: Incretin Analogues and a New Frontier in Cardiovascular Therapeutics  /  How are incretins PIONEERing metabolic care? Mechanisms of weight loss and risk factor reduction with incretin analogues
Logo

American Heart Association

  2
  0

Final ID:

How are incretins PIONEERing metabolic care? Mechanisms of weight loss and risk factor reduction with incretin analogues

  • Nauck, Michael  ( St Josef-Hospital , Bochum , Germany )
  • Drucker, Daniel  ( University of Toronto , Toronto , Ontario , Canada )
  • Pratley, Richard  ( AdventHealth Orlando , Orlando , Florida , United States )
    • Author Disclosures:
    Michael Nauck: DO have relevant financial relationships ; Consultant:Boehringer-Ingelheim:Active (exists now) ; Speaker:NovoNordisk:Active (exists now) ; Speaker:Medscape:Active (exists now) ; Speaker:Medical Learning Institute:Past (completed) ; Speaker:Eli Lilly & Co.:Active (exists now) ; Speaker:AstraZeneca:Active (exists now) ; Research Funding (PI or named investigator):Merck, Sharp & Dohme:Past (completed) ; Consultant:Sun Pharma:Active (exists now) ; Consultant:Structure Therapeutics:Active (exists now) ; Consultant:Regor:Active (exists now) ; Consultant:Pfizer:Active (exists now) ; Consultant:NovoNordisk:Active (exists now) ; Consultant:Eli Lilly & Co.:Active (exists now) | Daniel Drucker: DO have relevant financial relationships ; Consultant:altimmune:Active (exists now) ; Speaker:Zealand:Past (completed) ; Speaker:Boehringer Ingelheim:Past (completed) ; Consultant:Pfizer:Active (exists now) ; Consultant:Novo Nordisk:Past (completed) ; Consultant:Merck:Active (exists now) ; Consultant:Kallyope:Active (exists now) ; Consultant:AstraZeneca:Active (exists now) ; Consultant:Amgen:Active (exists now) | Richard Pratley: DO have relevant financial relationships ; Consultant:AbbVie Inc.; Bayer AG; Pfizer:Active (exists now) ; Consultant:Intas Pharmaceuticals Inc.:Past (completed) ; Speaker:Lilly USA LLC; Novo Nordisk:Active (exists now) ; Consultant:Genprex; Getz Pharma; Sun Pharmaceuticals:Past (completed) ; Consultant:Gasherbrum Bio, Inc.; Scholar Rock Inc.:Active (exists now) ; Researcher:Fractyl; Novo Nordisk; Sanofi:Active (exists now) ; Consultant:Endogenex Inc.; Novo Nordisk:Active (exists now) ; Consultant:Rivus Pharmaceuticals Inc.:Active (exists now) ; Researcher:Dompe; Endogenex Inc.:Active (exists now) ; Consultant:Corcept Therapeutics Incorporated:Active (exists now) ; Researcher:Carmot Therapeutics:Active (exists now) ; Researcher:Biomea Fusion; Lilly; Scholar Rock Inc.:Active (exists now) ; Consultant:Bayer HealthCare Pharmaceuticals Inc.:Active (exists now) ; Consultant:Eli Lilly; Lilly USA LLC:Active (exists now) ; Consultant:AstraZeneca Pharmaceuticals LP:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

GLP-1RAs and Beyond: Incretin Analogues and a New Frontier in Cardiovascular Therapeutics

Sunday, 11/17/2024 , 09:45AM - 11:00AM

Main Event

More abstracts on this topic:
Patient Interview

Ndumele Chiadi, Taub Pam

Panel Discussion

Tuttle Katherine

More abstracts from these authors:
Panel Discussion

Nauck Michael, Drucker Daniel, Pratley Richard

Once Weekly Utreglutide (GL0034), a Glucagon-like Peptide-1 Receptor Agonist, at 4 × 450 µg Doses Reduces Blood Pressure, Lipids, and Body Weight in Post-menopausal Females: A Phase I Study

Thennati Rajamannar, Vilsboll Tina, Burade Vinod, Natarajan Muthukumaran, Shahi Pradeep, Nagaraja Ravishankara, Agrawal Sudeep, Duvauchelle Thierry, Pratley Richard, Thorens Bernard

You have to be authorized to contact abstract author. Please, Login
Not Available